Experimental and clinical studies are progressing simultaneously to investigate the mechanisms and efficacy of progenitor cell treatment after an acute myocardial infarction and in chronic congestive heart failure. Multipotent progenitor cells appear to be capable of improving cardiac perfusion and/or function; however, the mechanisms still are unclear, and the issue of whether or not trans-differentiation occurs remains unsettled. Both experimentally and clinically, cells originating from different tissues have been shown capable of restoring cardiac function, but more recently multiple groups have identified resident cardiac progenitor cells that seem to participate in regenerating the heart after injury. Clinically, cells originating from blood or bone marrow have been proven to be safe whereas injection of skeletal myoblasts has been associated with the occurrence of ventricular arrhythmias. Myoblasts can transform into rapidly beating myotubes; however, thus far convincing evidence for electro-mechanical coupling between myoblasts and cardiomyocytes is lacking. Moving forward, mechanistic studies will benefit from the use of genetic markers and Cre/lox reporter systems that are less prone to misinterpretation than fluorescent antibodies, and a more convincing answer regarding therapeutic efficacy will come from adequately powered randomized placebo controlled trials. Gene Therapy (2006) 13, 659-671.
In brief Progress
Multiple cell types seem capable of improving myocardial perfusion and/or function in cardiac regenerative therapy, but reported study results vary and improved laboratory techniques are needed to understand the discordant data. Since 2002 clinical studies have accumulated evidence for a biological effect both in congestive heart failure and in the setting of acute myocardial infarction.
Prospects
The randomized clinical trials that are currently in progress will help us decide whether the encouraging results of the small, mostly nonrandomized studies reported to date translate into a clinically significant effect and whether treatment with skeletal myoblasts and bone marrow derived progenitor cells is safe. In the laboratory, there have been improvements in our ability to identify multipotent cells in animal models of cardiac regenerative therapy. The use of genetic markers that can be identified without antibodies will enable us to determine with more confidence the mechanism of beneficial effects of cell transfer to the injured heart. In order to understand and quantify the effect of cell therapy in patients, imaging techniques that allow the cells to be tracked and their viability ascertained over time will need to be combined with serial assessment of cardiac function and perfusion. Issues of dose, cell type, optimal delivery method and location need to be investigated in more depth. In parallel with ongoing clinical trials, it is anticipated that experimental work will focus on modulating cardiac inflammatory and fibrotic responses, methods for ex vivo
Introduction
The perceived phenotypic plasticity of many types of progenitor cells in vitro, together with the evidence of successful engraftment and functional improvement in animal models of myocardial infarction (MI) and heart failure following transplantation of various cell types into the damaged myocardium, 1,2 has led to the initiation of clinical studies of cell therapies in patients with heart disease. These strive to address whether administration of various cell types including various fractions or indeed unfractionated peripheral blood or bone marrow mononuclear cells can improve cardiac perfusion and function in the setting of acute or chronic ischemia [3] [4] [5] [6] and whether skeletal myoblasts or bone marrow cells can improve chronic congestive heart failure (CHF). 7, 8 This review will address the current state of cell therapies in the cardiovascular field concentrating on two principal areas: acute myocardial ischemia and chronic CHF.
Reported study results vary and improved laboratory techniques are needed to understand the discordant data
While virtually all studies of cell transfer into damaged cardiac tissues reported functional benefits, especially in small animal models, the mechanism of these effects remains unresolved. Initial reports suggesting transdifferentiation of cells delivered to target tissues into the organ host cells have been followed by reports of cell fusion and by claims of no meaningful cell-cell transformation, leading to a major controversy. The evidence for trans-differentiation in vivo is contradictory with some studies finding evidence for phenotypic switches following injections of cells into the heart or other organs [9] [10] [11] while others cannot demonstrate this phenomenon. [12] [13] [14] [15] The reasons for these discrepancies are manifold and include both technical as well as poorly understood biological issues. Studies relying on immunohistochemistry with fluorescently tagged antibodies are prone to error because of high background fluorescence caused by the high density of cardiac contractile proteins, collagen and macrophages in the infarct area, and antibodies may bind nonspecifically to abundant muscle proteins. Studies using reporter genes such as EGFP and b-galactosidase, or Y chromosome fluorescence in situ hybridization (FISH) 16 allow for easier recognition of the transplanted cells. The application of the Cre/lox reporter system to this problem 17 is an example of progress in this direction. In contrast to a highly controversial trans-differentiation, cell fusion is a well-recognized phenomenon, even if the reports differ as to the frequency with which this event occurs. The existence of cell fusion has been clearly demonstrated in several organs [17] [18] [19] although its functional significance has not been determined. The combination of reporter genes and the Cre/lox system has also been used to study cell fusion in vivo. 17 More recently, cells have been shown to establish connections via nanotubules that facilitate intercellular transport of macromolecules, and this could be an alternative explanation for phenotype switches of injected multipotent cells. 20 Cell integration, another plausible mechanism of cell transfer benefit, refers to the ability of certain cell types such as skeletal myoblasts, to integrate into the cardiac syncytium without trans-differentiating into the cardiac muscle in the process improving cardiac performance. Electromechanical coupling between the transplanted skeletal myoblasts and the myocardium 17, 21 would contribute to this functional integration, although its existence has been challenged. 22 Another potential mechanism of the observed beneficial effects is the possibility that cell transfer can stimulate proliferation and/or differentiation of endogenous progenitors, based on a paracrine effect of transplanted cells (i.e. release of various chemokines and cytokines that can affect endogenous cell differentiation, myocardial remodeling and function). [23] [24] [25] [26] [27] It has been shown that endothelium-derived growth factors affect the development of apparently unrelated organs and cells, and a paracrine effect has also been demonstrated for other cell types. Thus, Akt-1-transfected mesenchymal progenitor cells have been shown to protect the ischemic heart via a paracrine mechanism. 28 Yet another potential mechanism involves a brain-derived neurotrophic factor (BNDF) that has been shown to promote neovascularization by simultaneously attracting a subpopulation of local endothelial cells that express the BNDF receptor, and recruiting hematopoietic progenitors from the bone marrow to ischemic skeletal muscle. 29 Finally, the mechanical effects of cell transfer (i.e. strengthening of the scar by the presence of a new tissue mass) may but itself favorably alter LV geometry and improve cardiac function.
Stem cells can give rise to every cell type whereas progenitor cells have a more limited differentiation potential
The increasing number of studies evaluating a multitude of cell types underscores the need for rigorous definition of the cell types that are being studied. Some progenitor cells in adult organs, such as spermatogonial cells in the testes, are unipotent and produce one type of differentiated cell, the spermatozoon. Other cells, such as bone marrow progenitor cells, are multipotent and produce erythrocytes and all types of white blood cells. A true 'stem' cell distinguishes itself from unipotent and multipotent progenitor cells by its ability to give rise theoretically to every cell type. A stem cell is clonogenic, capable of unlimited self-renewal by symmetric division, while maintaining a stable diploid karyotype. It is also capable of asymmetric division, one daughter resembling its mother, and one daughter giving rise to multiple types of differentiated cells. The progenitor cells that have been identified in adult organs thus far do not meet these criteria, and therefore we propose to use the term stem cell only for embryonic stem cells, and refer to all other cells as (multipotent) progenitor cells.
In the embryo, the blastocyst gives rise to embryonic stem cells, which in turn give rise to the hemangioblast. It is not known whether the hemangioblast persists in adult life, and until recently only hematopoietic progenitor cells and endothelial progenitors have been identified in adult patients and mice. The definition of an endothelial progentitor cells (EPC) has been elusive as various labs have used different approaches to their isolation and characterization. It is assumed that these cells express the receptor for vascular endothelial growth factor, VEGFR2, which is absent from some but likely not all hematopoietic stem cells, and they are further characterized by the cell surface markers CD133, and, In-oxine, 111 Indium-oxine; i.v., intravenous; LCX, left circumflex coronary artery; LV, left ventricular; LVH, left ventricular hypertrophy; MHC, myosin heavy chain; MI, myocardial infarction; MPC, mesenchymal progenitor cells; n.a., not applicable; n.r., not reported; SMA, smooth muscle actin; SMB, skeletal myoblasts; SPC, side population cells; TnI, troponin I; TnT, troponin T; vWf, von Willebrand factor. 
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potentially, by the nonlineage specific marker CD34. 30 The exact relationships among these markers have not been established, however. The various types of stem and progenitor cells are summarized in Table 1 and Figure 1 .
Mutiple cell types are capable of improving myocardial perfusion and/or function in cardiac regenerative therapy
In discussing various cell types used for therapeutic cardiovascular applications, it is important to distinguish between three principal uses: acute myocardial ischemia, chronic myocardial or limb ischemia and CHF. The two former applications include primarily facilitation of angiogenesis combined, in the setting of acute myocardial ischemia, with tissue salvage, while the latter application primarily deals with augmentation of myocardial contractility although at present most likely to be achieved via angiogenesis. Table 2 summarizes the clinical studies with different cell types.
Endothelial and endothelial-progenitor cells
All progenitor cells are rare and, furthermore, their numbers and functional capacity decrease with a person's age and other risk factors for coronary artery disease. Recently, the amount of circulating EPC has been shown to correlate inversely with the risk for cardiovascular events. 31, 32 While the size of the EPC population has not been conclusively determined, in part because of uncertainties regarding their markers, CD34 + cells constitute o1% of circulating mononuclear cells while CD133 + are even less frequent. Both circulating and Figure 1 ). Hemangioblasts can be derived from blastocyst derived embryonic stem cells, and in vivo they arise from the yolk sac or AGM region of the early embryo. Upon appropriate stimulation in vitro, hemangioblasts develop into hematopoietic progenitor cells that can give rise to all cell lines of the lymphoid and hematopoietic system, or they can develop into angioblasts that form endothelial cells and capillaries. In adult bone marrow self-renewing cells differentiate into hemangioblasts that generate all cells of hematopoietic lineage, but cells of monocyte lineage can also differentiate into endothelial cells. The origin of the multipotent adult progenitor cell is unknown, but its progeny forms all mesenchymal tissues, and it can differentiate into cardiomyocytes and endothelial cells. Skeletal muscle is of mesenchymal lineage and can dedifferentiate into a myoblast phenotype, and then can differentiate into a cell with cardiomyocyte features. In adult myocardium, several multipotent cells have been identified by immunohistochemistry and fluorescence-activated cell sorting, and by sorting for side population cells. These cells have been shown to differentiate into endothelial cells and capillaries, cardiomyocytes and vascular smooth muscle cells.
Regenerative therapy for cardiovascular disease ED de Muinck et al 33 Furthermore, EPC and monocytes share a number of functional characteristics, including the ability to internalize acetylated LDL and to bind lectins. 30 Indeed, different starting populations that include peripheral blood mononuclear cells can all give rise to cells that express endothelial marker proteins such as von Willebrand factor, VE-cadherin, CD146 and CD31, and that are capable of forming endothelial cell colonies, and that show increased e-NOS expression in response to shear stress. 23, 34 EPC and mature endothelial cells can be distinguished, however, based on different growth kinetics in vitro. When plated on collagen or fibronectin and incubated with VEGF, IGF and FGF, mature endothelial cells form colonies that have a low proliferation potential and appear early, after 9 days in culture. In contrast, EPC form colonies that appear late, after 20 days of culture, and have a high proliferative index. 30 In addition, mature endothelial cells lack expression of CD133, a stem cell marker with unknown function that is expressed on some but not all EPC populations. 35 Thus, a more rigorous definition of EPC would combine cell surface markers and growth kinetics. For example, EPC can be defined as a subpopulation of CD34 + leukocytes that express VEGFR2 + and CD133 + , and form lateoutgrowth endothelial colonies.
Mononuclear cells
Improvements in myocardial perfusion and cardiac function can also be obtained by injecting bone marrowor peripheral blood-derived mononuclear cells. [3] [4] [5] [6] 8, [36] [37] [38] As should be clear from the previous discussion, in many cases it is difficult to ascertain the differences between endothelial progenitor and nonendothelial progenitor cell populations. This is illustrated by the recent identification of a subpopulation of cells that has an abundant expression of the monocyte marker CD14 and very low levels of CD34. However, these cells displayed characteristics of EPC, and were capable to mature into endothelial cells. 39 Since most mononuclear cell populations contain EPC as well as hematopoietic progenitors, such coadministration of endothelial and hematopoietic progenitors may lead to initiation and sustenance of neovascularization. 30 
Side population cells
Side population (SP) cells are selected on the basis of their capability to extrude Hoechst 33342 dye, and this capability is conferred by the expression of the ATPbinding cassette (ABC) transporter Abcg2/brcp1, which is restricted to the SP population. 40 Interestingly, forced expression of this transporter gene confers an SP phenotype, underlining the functional importance of the gene in determining this progenitor cell phenotype. 41 These cells were originally identified in bone marrow where they account for 0.05% of the total cell population, but later studies have identified SP cells in a variety of tissues including the adult heart, 42, 43 and multilineage differentiation capability has been established for all SP cells regardless of their tissue of origin. 40 The distinct staining pattern, conveyed by a high level of dye efflux Regenerative therapy for cardiovascular disease ED de Muinck et al activity, allows SP cells to be isolated by fluorescence activated cell sorter (FACS), as they fall within a separate population to the side of the rest of the cells on a dot-plot of emission spectra in the blue rather than in the red spectrum.
Mesenchymal progenitor cells
During embryonic development, cardiomyocyte progenitors arise from the lateral plate mesoderm under stimulation from differentiation factors secreted from the adjacent endoderm, whereas the bone marrow is derived from the somatic mesoderm. Despite these differences in origin, several studies show that bone marrow-derived mesenchymal progenitor cells can acquire a cardiomyocyte phenotype under certain conditions in vitro and in vivo. These cells are capable of differentiating into cells with cardiomyocyte features in vitro, either through coculture with cardiomyocytes 44 or exposure to 5-azacytidine, 45 a cysteine analog capable of altering the expression of certain genes that may regulate differentiation. The cells are positive for b-myosin heavy chain, cardiac troponin T, a-cardiac actin and desmin. 45 Furthermore, these cells exhibit Ca 2+ transients, several types of action potentials and respond to a and b adrenergic stimulation with an increase in contractility, phosphorylation of ERK1/2 and an increase in cAMP. 45 After injection in vivo, mesenchymal progenitor cells tagged with 99m Tc 46 were detected in the heart, and the lac-Z positive cells showed phenotypic features of cardiomyocytes on immunohistochemical examination.
Importantly, MPC exhibit low immunogenicity and they posses immuno-regulatory functions, 47 ,48 making them especially attractive for cardiac regenerative therapy. They posses a cell surface phenotype that is poorly recognized by T cells, because of the absence of major histocompatibility class II antigen, and T cell costimulatory molecules such as B7-1, B7-2, CD40 and CD40 ligand. 47, 48 With respect to their immuno-regulatory function, MPC have been shown to suppress T-cell responses in vitro, 49 and this effect may be mediated partially by the secretion of cytokines such as TGF-b and HGF. 50 The low immunogenicity of MPC may allow for the generation of an 'off-the-shelf' cell product based on these cells, that may be injected immediately when the need arises, for example, as an adjunct to percutaneous coronary reperfusion in the setting of acute MI.
Other bone marrow derived progenitor cells
For the first time, a cell type has been cultured recently from human bone marrow that is capable of expansion from a single cell, shows unlimited self-renewal, and has been shown to be able to differentiate into endothelial cells, smooth muscle cells and cardiomyocytes. 51 Fluorescence activated cell sorting showed that this cell type does not belong to previously identified populations of multipotent bone marrow-derived cells.
Resident cardiac progenitor cells
Groups of small cells that are negative for blood lineage marker (Lin 54 These cells lacked other blood cell markers (CD4, CD8, B220, Gr-1, Mac-1, and TER119), and endothelial markers (VEGFR1, VEGFR2, VE-cadherin, von Willebrand factor) and the stem cell markers c-kit, CD45 and CD34. They did express CD31 or its receptor CD38. Transcription profiling showed that the sca-1 + cells expressed most cardiogenic transcription factors but not cardiac structural genes, and in keeping with their self-renewing potential, telomerase activity was detectable in these cells. Using a Cre/lox donor/ reporter system, homing, differentiation and fusion of these sca-1 + cells could be demonstrated in a mouse model of myocardial ischemia/reperfusion injury. Recently, cardiac progenitors defined by coexpression of ckit, MDR1 and sca-1 were isolated from human hearts, 55 and in animal models of MI they were shown to be mobilized from the atria to the infarct zone after a gradient of hepatocyte growth factor and insulin-like growth factor 1 had been applied to the heart. 56, 57 Another group of resident cardiac progenitor cells is characterized by the expression of the antigen 'islet 1' (isl1), and these isl1+ cells develop into cells with a mature cardiac phenotype including intact Ca 2+ -cycling and the generation of action potentials. 58 As mentioned earlier, SP cells can be isolated from the heart, and thus constitute a fifth cardiac progenitor phenotype that can acquire an adult cardiomyocyte phenotype when placed in a permissive environment. 42, 43 Finally, cells have been isolated from myocyte depleted fractions of murine and human atria and ventricles that form spheres when cultured in 'cardiosphere growing medium'. 59 The cells that compose these spheres are clonogenic, and the cells of murine origin develop into spontaneously contracting units upon continued culture, whereas the human cells have to be cocultured with rat cardiomyocytes to develop a contractile phenotype. The cardiosphere cells express the endothelial markers KDR (human)/flk-1(mouse) and CD31, as well as the stem cell markers CD34, sca-1 and c-kit. When injected into the myocardium in SCID mice immediately after MI, they acquired phenotypic markers of cardiac cells such as lamin A/C, a human cardiomyocyte marker and connexin-43. They also incorporated into capillaries and larger vessels, where they stained for CD31 and a-smooth muscle actin, respectively (Table 1) .
In summary, the demonstration of resident cardiac progenitors in these studies, and their documented contribution to repair of cardiac injury when administered exogenously, opens the possibility of restoring cardiac function through mobilizing these cells to injured myocardium as well as through cell transplant strategies. The discovery of human cardiac progenitor cells that acquire cardiomyocyte markers in an MI model in particular may bring this approach closer to clinical reality. Future studies will be needed to establish
whether or not these different progenitors share a common ancestry during embryonic development.
Cells of mesenchymal origin from other organs are multipotent and can improve cardiac function Skeletal myoblasts. Skeletal myoblasts can be obtained in culture from single myofibers isolated from adult skeletal muscle. These cells have been shown to engraft in MI models and to contribute to functional improvement of cardiac function. 1, [60] [61] [62] The mechanism of this functional improvement is not clear, but myoblasts labeled genetically with GFP, have been shown to differentiate into hyperexcitable myotubes with a contractile activity fully independent of neighboring cardiomyocytes. 22 Evidence for electro-mechanical coupling to cardiomyocytes is provided by observations from twophoton molecular excitation (TPME) laser scanning microscopy of EGFP-expressing myoblasts after transplantation into adult hearts. Transients of intracellular Ca 2+ concentration [Ca 2+ ] i were observed that were synchronous with the transients in the host cardiomyocytes. 21 Importantly, after transplanting EGFP labeled myoblasts into hearts with cardiomyocyte restricted expression of the LacZ gene, there was a small population of cells that expressed both the donor and host marker genes, indicating fusion between donor and host cells. The location of these cells was very similar to the functionally coupled cells that had been identified earlier by TPME imaging. Moreover, connexin-43 was readily detectable in the junctions between the fused cells and the host cardiomyocytes, thus making it likely that the synchronicity of [Ca 2+ ] i transients is a result of fusion between host and donor cells and functional coupling of these fused cells and host cardiomyocytes. 21 Other evidence for myoblast and cardiomyocyte fusion comes from experiments that employed a Cre/lox reporter system that activated LacZ only upon cell fusion. FloxedLacZ myoblasts injected into hearts of mice that had cardiac restricted expression of Cre (a-MHC-Cre) were shown to fuse with cardiomyocytes. 17 The allure of a nonimmunogenic, autologous cell integrating into injured myocardium with possible trans-differentiation into rapidly contracting units has stimulated the initiation of clinical trials, which will be discussed below. To date, the evidence for electro-mechanical coupling between myoblasts and cardiomyocytes is indirect with no in vivo demonstration of synchronously contracting cardiomyocytes and myoblasts.
Stromal cells from adipose tissue. Stromal, nonadipocyte cells from adipose tissue have the capacity to differentiate into other cells of mesenchymal lineage including adipocytes, osteoblasts, chondrocytes, and myoblasts, and they have been shown to be capable of re-populating bone marrow of lethally irradiated mice. 63 Importantly, they have been reported to differentiate spontaneously into cells with phenotypic characteristics of cardiomyocytes, without treatment with the DNA demethylation agent 5-azacytidine, which has been necessary to induce cardiomyocyte phenotypes in mesenchymal progenitors. 64 Once differentiated, they were responsive to isoproterenol, propranalol, carbamylcholine, and atropine, and expressed several cardiacspecific mRNA such as Nkx2-5, GATA4, ventricular and atrial myosin light chain, and natriuretic peptide. These cells have been shown to act as a source of angiogenic cytokines, they can undergo endothelial differentiation in vitro, and contribute to neo-vascularization and functional recovery in mouse hind limb ischemia models. 65, 66 Embryonic stem cells. An important difference between ES cells and other progenitors is that the former in theory can give rise to all the cell types in the body, while all other cells have limited plasticity. In a mouse model of congenital heart disease, ES cells have been able to rescue the cardiac defect, 67 and in MI models they have contributed significantly to restoration of cardiac function, with evidence for long-term benefit of ES cell transfer. 68 Multiple issues presently prevent therapeutic application of ES cells in patients, including the need for reliable human ES cell differentiation protocols, purification techniques for the different progeny, circumvention of the immunological rejection of the transplanted cells, and ethical issues centering on the use of human embryos. The 'immunoprivileged' status of ES (and MSC) cells is not well understood and it is not clear, for example, whether it will continue after these cells differentiate into mature adult cell types. One approach to circumvent this issue has been the successful application of somatic cell nuclear transfer (SCNT). This technique, also known as 'therapeutic cloning', involves the transfer of the nucleus of a somatic cell into an enucleated donor oocyte. In theory, the oocyte's cytoplasm would reprogram the transferred nucleus by silencing all the somatic genes and activating the embryonic genes. The ES cells that would be isolated from the ICM of the preimplantation embryo would only carry the nuclear genome of the patient, thus creating a nonimmunogenic ES cell. Recently, SCNT has led to the successful derivation of human ES cells that were genetically identical to the somatic nuclear donor cells. 69 Regarding cardiac regenerative therapy, it remains to be seen whether human ES cells will be the optimal form of cell-based therapy, in light of other available multipotent progenitors some of which are already in clinical trials.
Early clinical studies have accumulated evidence for a biological effect both in CHF and in the setting of an acute MI Early clinical investigations of cardiac cellular transplantation have been performed in patients with chronic ischemic cardiomyopathy and heart failure (both with a nonviable scar as well as viable ischemic tissues), with and without adjunctive revascularization, as well as early after MI.
Chronic CHF Skeletal myoblast therapy. The principal rationale for application of cell therapy to treatment of chronic CHF has been the concept of myocardial regeneration, as any neovascularization in response to cell therapy in this setting is thought to have a less pronounced effect on restoration of cardiac function. A limited phase I study has been reported in a patient subset with severe left ventricular systolic dysfunction (ejection fraction p35%), postinfarction akinetic or nonviable scar, and indication for coronary artery bypass surgery (CABG) in remote areas. An average of 8.7 Â 10 8 autologous skeletal myoblasts were implanted by direct injection into nonviable zones at the time of CABG. 7 One nontransplant related early death occurred and four patients had sustained ventricular tachycardia requiring intracardiac defibrillator (ICD) placement. At nearly 11 months followup, ejection fraction had improved from 24% to 32% overall, and blinded echocardiographic analysis demonstrated improved thickening in 63% of myocardial scars receiving myoblast injection. 7 While quite interesting, the ability to draw conclusions about efficacy of such therapy in these studies has been limited by the concomitant CABG and the open label format of this trial.
Similar findings have been reported by other investigators. Siminiak et al. 70 presented 10 patients with postinfarction heart failure and myocardial scar who received intramyocardial myoblast injections as adjunctive treatment during CABG, and found an improvement in overall left ventricular systolic function in their cohort. Pagani et al. 71 reported five patients who had autologous skeletal myoblast direct myocardial injections at the time of implantation of a left ventricular assist device to bridge for orthotopic cardiac transplantation. After explantation, skeletal myoblasts were shown to persist in three hearts up to 191 days after injection, suggesting that in patients cells can morphologically engraft and be present for extended time periods. Smits et al. evaluated the utility of catheter-based skeletal myoblasts injection in five patients with myocardial scar and ejection fraction between 20% and 45%. Mean ejection fraction increased from 36% to 45% with a parallel increase in target wall thickening in the injected areas. 72 The favorable results of these trials have prompted a more comprehensive evaluation of skeletal myoblast transfer in larger double-blind trials, which utilize direct myocardial injection in the setting of CABG surgery, or catheter-based transendocardial cell delivery.
Bone marrow mononuclear cells. Unlike skeletal myoblast therapy where skeletal to cardiac myocyte trans-differentiation is not required to achieve functional benefit, injection of bone-marrow derived cells heavily relies on the trans-differentiation concept as its intellectual underpinning. A nonrandomized, uncontrolled, open label study of trans-endocardial injections of bone marrow mononuclear cells in patients with systolic dysfunction and heart failure without a revascularization option was carried out in 21 patients. PET imaging demonstrated a significant reduction in reversible ischemic defects at 2 months follow-up. In addition, mean ejection fraction was improved and systolic volumes were favorably reduced. 8, 73 The improved perfusion may indicate that the principal effect of cell transfer was stimulation of angiogenesis leading to improved cardiac performance as a secondary effect.
Acute MI
The use of bone marrow and peripheral blood mononuclear cell transfer is being extensively investigated in the setting of acute MI. In the Transplantation Of Progenitor Cells And Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) trials, MRI after 1 year demonstrated improved ejection fraction, reduced infarct size, and absence of reactive hypertrophy compared to historic controls. 74 The similar BOOST trial compared standard, optimum postinfarction medical therapy vs optimum therapy plus administration of bone marrow-derived mononuclear cells via coronary infusion. At 6-month follow-up, the ejection fraction increased 0.7% in the control arm and by 6.7% in the treatment group. 6 The regional improvement in the wall motion was seen predominantly in the periinfarct area. No differences in adverse outcomes were demonstrated between groups. Interestingly, 18 months later, the differences between the groups became nonsignificant due to continuous improvement in the control group (BOOST presentation, AHA 2004).
In summary, only two trials thus far have randomized patients to cell therapy or alternative treatment. In the BOOST trial, this was standard post-MI therapy, and therefore the control group was sub-optimal for lack of a placebo group. Recently, the first randomized comparison of bone-marrow cells vs placebo as adjunctive therapy to percutaneous revascularization of acute MI was presented. 75 At 4 months follow-up, the infarct size in the bone-marrow cell group was significantly smaller. However, there were no differences in improvement of systolic function and myocardial perfusion by MRI, and no differences in oxidative metabolism by PET.
Chronic total occlusion. One recent study evaluated the use of bone marrow derived progenitors as adjunctive treatment after recanalization of a chronic total coronary artery occlusion (CTO). 76 A total of 26 patients were randomized to receive either progenitor cells or placebo after successful recanalization of the CTO. At 3 months follow-up, there were indications of improved vascularization in the treatment group, as shown by a significant improvement of coronary flow reserve and a significant reduction in the amount of hibernating myocardium as measured by 18 F deoxyglucose positron emission tomography.
Prospects
More stringent evaluation of the evidence for a biological effect of clinical cell therapy is currently underway in several randomized clinical trials, some of which are placebo controlled. Apart from the results of these trials, the field will be able to advance with more confidence when cell imaging methods become available that allow injected cells to be tracked over time and that will enable the determination of cell viability after injection. The combination of these methods with readouts of cardiac perfusion and function will generate a better understanding of how multipotent cells improve cardiac function in patients. Issues of dose, cell type, delivery method and delivery location in the heart will need further attention.
Experimentally, it is anticipated that a better understanding of therapeutic mechanisms will be gained using genetic markers and improved versions of the Cre/lox system. This technique holds significant promise for the assessment of the relevance of fusion vs trans-differentiation for cell-based improvement of cardiac function. Efforts to manipulate cells ex vivo to direct them towards a desired phenotype are gaining momentum, and these will hopefully help to mitigate inflammation and Regenerative therapy for cardiovascular disease ED de Muinck et al scarring as well as the propensity for life threatening arrhythmia. 77, 78 Homing and engraftment of circulating cells and the microenvironmental cues that dictate survival and proliferation of cells are areas that are anticipated to see a sustained scientific commitment, and as a result of this the application of implantable scaffolds to serve as an optimized microenvironment for cell survival, differentiation and proliferation may become an important adjunct to cardiac cell therapy.
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Conclusions
The opportunities of cardiac cell based regenerative therapy need to be harnessed while fully taking into account the hurdles that need to be overcome before cellbased therapy can become a clinical reality. The beneficial effects of cell therapy need to be understood in terms of their mechanisms, delivery methods need to be optimized, and proper clinical trials conducted to fully evaluate not only efficacy but also the safety of this novel therapeutic modality.
